Successful treatment of hepatocellular carcinoma with the tyrosine kinase inhibitor imatinib in a patient with liver cirrhosis.

Abstract

Several mechanisms of development of hepatocellular carcinoma (HCC) in patients with liver cirrhosis have been discussed. One hypothesis suggests that the somatic stem cells of the liver, the so-called oval cells, may undergo malignant transformation. Oval cells are derived from the biliary cells of the canal of Hering and are characterized by c-kit-positivity, the transmembrane receptor of stem cell factor. Constitutively activated tyrosine kinases have been identified as major pathogenetic mechanisms in the development of malignant diseases like gastrointestinal stromal tumors (c-kit) and chronic myelogenous leukemia (bcr-abl). The prognosis of these diseases improved enormously since the drug imatinib, a tyrosine kinase inhibitor of c-kit and bcr-abl, was introduced. Here we report the successful cure of a patient with liver cancer by this tyrosine kinase inhibitor.

• Authors: Giuliano Ramadori, Laszlo Füzesi, Eckhardt Grabbe, Tomas Pieler, Thomas Armbrust
• Journal: Anti-cancer drugs (Anticancer Drugs) Vol. 15 Issue 4 Pg. 405-9 (Apr 2004) ISSN: 0959-4973 [Print] England
• PMID: 15057146 (Publication Type: Case Reports, Journal Article)

Chemical References

• Antineoplastic Agents
• Benzamides
• Piperazines
• Pyrimidines
• Imatinib Mesylate
• Protein-Tyrosine Kinases

Topics

• Antineoplastic Agents (adverse effects, therapeutic use)
• Benzamides
• Carcinoma, Hepatocellular (complications, drug therapy)
• Humans
• Imatinib Mesylate
• Liver Cirrhosis (complications)
• Liver Diseases (complications, drug therapy)
• Male
• Middle Aged
• Piperazines (adverse effects, therapeutic use)
• Protein-Tyrosine Kinases (antagonists & inhibitors)
• Pyrimidines (adverse effects, therapeutic use)